CA: A Cancer Journal for Clinicians (CA) was not a journal I ever saw myself publishing in let alone leading; its impact factor and prestige seemed out of reach for me—such is the Imposter Syndrome. Still, I came across the opportunity to become its editor and I applied, thinking I would regret it if I did not at least try. To my delight, I was chosen to succeed Ted Gansler, who had led CA as its editor for 23 years. Unbeknownst to me, I would also be the first to lead the journal from outside of the American Cancer Society (ACS).

CA holds a special place in medicine, and specifically in oncology. Best known for the annual publication of Cancer Statistics, it is also the reference for a diverse readership, from primary care providers to advanced practice practitioners, both within the United States and globally. Therefore, it remains important that what we publish is accessible to all—regardless of whether they are specialized in cancer medicine. With that in mind, we have instituted new instructions for our potential authors, and they are based in intentionality. Articles submitted need to be understandable to our audience, and this is an opportunity to translate technical concepts into much more accessible language. I’ve asked the authors to be cognizant that our readership includes not only diverse health professionals but also people who themselves have experienced cancer, their caregivers, and advocates. As such, patient-centric language should be used. As examples, cancer should not be used as an adjective (e.g., breast cancer patients) nor should progression on treatment be referred to as a failure. The patient experience is also one that it is important to acknowledge, and I have challenged those who intend to submit to CA to incorporate patients’ points of view in the construction and the writing of articles and to include them as authors wherever it makes sense.

As we move into the future, I hope to make use of CA to democratize the access to important information; and, in 2024, CA will begin considering publication of high-impact clinical trial results. I intend the process to be a collaboration from the start, from gaging the appropriateness of phase 3 research for CA to timely peer review and publication, while maintaining the standards set above. Although this is a major shift in the past content CA has accepted, our editorial group at ACS believe this is an important step for CA, not only because of its eminence in medical publishing but because it represents an opportunity for everyone to access information that may change the standards of care. These articles will not be restricted—they will be free and downloadable at our journal’s website, just as CA content has always been.

Most of all, I want to ensure all who read and contribute to CA that the rigorous care that Dr. Gansler provided will continue. Articles are personally reviewed by me before formal submission and peer review. This is not meant to be onerous but to ensure that consistency and quality in writing are reflected in our journal, adhering to the direction we have set forth above.

It has been a great first year at CA, and I hope that, in small ways and some larger ones, it will continue to be a source for all interested in oncology—from prevention to treatment to survivorship and palliative care. This is the flagship journal of the ACS; and, as we look forward, we will bear this in mind in all that we publish and ensure that the progress in oncology is shared. With everyone.

With best regards,

Don S. Dizon, MD

Editor, CA: A Cancer Journal for Clinicians

CA：《临床医生癌症杂志》(CA)不是我自己发表过的期刊，更不用说领导了；它的影响因子和声望对我来说似乎遥不可及——这就是冒名顶替综合症。尽管如此，我还是遇到了成为其编辑的机会，并提出了申请，心想如果我不至少尝试一下，我会后悔的。令我高兴的是，我被选为接替特德·甘斯勒 (Ted Gansler) 的人，他作为编辑领导CA长达 23 年。我不知道的是，我也是第一个在美国癌症协会 (ACS) 之外领导该杂志的人。

CA在医学领域，特别是在肿瘤学领域占有特殊的地位。它以年度出版物《癌症统计》而闻名，也是美国和全球范围内从初级保健提供者到高级实践从业者的不同读者的参考资料。因此，让所有人都能访问我们发布的内容仍然很重要，无论他们是否专门从事癌症医学。考虑到这一点，我们为潜在作者制定了新的说明，它们是基于意向性的。提交的文章需要能够被我们的读者理解，这是将技术概念翻译成更容易理解的语言的机会。我要求作者认识到，我们的读者群不仅包括不同的健康专业人士，还包括本身患有癌症的人、他们的护理人员和倡导者。因此，应使用以患者为中心的语言。例如，癌症不应用作形容词（例如乳腺癌患者），也不应将治疗进展视为失败。患者的经历也是一个必须承认的重要经历，我向那些打算提交给CA的人提出了挑战，要求他们将患者的观点纳入文章的构建和写作中，并在任何有意义的地方将他们纳入作者。

当我们走向未来时，我希望利用CA来民主化重要信息的访问； 2024 年， CA将开始考虑发布高影响力的临床试验结果。我希望这个过程从一开始就是一个合作，从评估CA第三阶段研究的适当性到及时的同行评审和出版，同时保持上述标准。尽管这是CA过去接受的内容的重大转变，但我们 ACS 的编辑小组认为，这对CA来说是重要的一步，不仅因为它在医学出版领域的杰出地位，而且因为它为每个人提供了访问可能的信息的机会。改变护理标准。这些文章不会受到限制——它们将可以在我们期刊的网站上免费下载，就像CA内容一直以来一样。

最重要的是，我想确保所有阅读 CA 并为CA做出贡献的人，甘斯勒博士提供的严格护理将继续下去。文章在正式提交和同行评审之前均由我亲自审阅。这并不意味着繁琐，而是为了确保我们的期刊反映写作的一致性和质量，遵循我们上面提出的方向。

这是在CA的第一年，我希望，无论是小方面还是大方面，它将继续成为所有对肿瘤学感兴趣的人的来源——从预防到治疗，再到生存和姑息治疗。这是 ACS 的旗舰期刊；展望未来，我们将在发布的所有内容中牢记这一点，并确保共享肿瘤学的进展。与大家一起。

 最诚挚的问候，

 唐·S·迪宗（Don S.Dizon），医学博士

加利福尼亚州编辑：临床医生癌症杂志